Zhang Henan, Liu Yunpeng
Grade 2008, Seven-year System, Department of Clinical Medicine, China Medical University, Shenyang110001,China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Aug;38(8):857-62. doi: 10.3969/j.issn.1672-7347.2013.08.017.
Small cell lung cancer (SCLC) are divided into limited and extensive stage diseases. Limited-stage SCLC (LS-SCLC) is confined to the ipsilateral hemithorax and within a single radiotherapy region, 30%-40% of patients with SCLC are limited stage. The median ranges of survival for patients with LS-SCLC is from 15 to 20 months. Approximately 20%-40% of patients with LS-SCLC can survive for two years. According to the guidelines, patients with LS-SCLC should be treated with combined concurrent chemoradiotherapy and patients with LS-SCLC achieving a complete remission or patient with stage I disease who have had resection should be offered prophylactic cranial irradiation (PCI). Whereas in SCLC, targeted therapies is still in the early stage and few clinical trial data is available to support its effect.
小细胞肺癌（SCLC）分为局限期和广泛期疾病。局限期小细胞肺癌（LS-SCLC）局限于同侧半胸且在单一放疗区域内，30%-40%的小细胞肺癌患者为局限期。LS-SCLC患者的中位生存范围为15至20个月。约20%-40%的LS-SCLC患者可存活两年。根据指南，LS-SCLC患者应接受同步放化疗，而对于达到完全缓解的LS-SCLC患者或已接受手术的I期疾病患者，应给予预防性颅脑照射（PCI）。而在小细胞肺癌中，靶向治疗仍处于早期阶段，几乎没有临床试验数据支持其疗效。
